Exhibit 10.2

______________________________________________________________________________

CO-PROMOTION AGREEMENT

by and between

DOVA PHARMACEUTICALS, INC. and

VALEANT PHARMACEUTICALS NORTH AMERICA LLC

September 26, 2018

______________________________________________________________________________

CONFIDENTIAL {E144 TREATMENT}  HAS   BEEN   {E145 REQUESTED}  FOR PORTIONS OF THIS EXHIBIT. THE COPY  {E2 FILED}  HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY {E145 REQUEST}. OMISSIONS  ARE   {E3 DESIGNATED}  [***]. A COMPLETE VERSION OF THIS EXHIBIT  HAS   BEEN   {E4 FILED}  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Source: DOVA PHARMACEUTICALS INC., 10-Q,  11/8/2018

TABLE OF CONTENTS

Page

ARTICLE 1 DEFINITIONS 1

ARTICLE 2 RIGHTS AND OBLIGATIONS 8

2.1 Engagement; Grant of Rights. 8

2.2 Retention of Rights. 9

2.3 Non-Competition; Non-Solicitation. 9

2.4 Dova Trademarks and Copyrights.  10

ARTICLE 3 JOINT STEERING COMMITTEE 11

3.1 Formation of the JSC.  11

3.2 Meetings and Minutes.  11

3.3 Purpose of the JSC.  11

3.4 Decision Making.  13

3.5 Marketing Sub-Committee.  13

ARTICLE 4 VALEANT ACTIVITIES FOR THE PRODUCT 14

4.1 Valeant Activities.  14

4.2 Detailing.  15

4.3 Compliance with Applicable Law.  17

4.4 Field Force Personnel Training; Product Materials.  19

4.5 Provisions  {E5 Related}  to Field Force Personnel.  21

4.6 Responsibility for Valeant Activity Costs and Expenses.  22

4.7 Data Sharing.  22

ARTICLE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL MATTERS 23

5.1 Dova Responsibility.  23

5.2 Valeant Involvement.  23

5.3 Inspections.  23

5.4 Pharmacovigilance.  24

5.5 Unsolicited Requests for Medical Information.  24

5.6 Recalls and Market Withdrawals.  25

5.7 Certain Reporting Responsibilities.  25

5.8 Booking of Sales Revenues.  25

5.9 Returns.  25

Source: DOVA PHARMACEUTICALS INC., 10-Q,  11/8/2018

i

CONFIDENTIAL {E146 TREATMENT}  HAS   BEEN   {E147 REQUESTED}  FOR PORTIONS OF THIS EXHIBIT. THE COPY  {E7 FILED}  HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY {E147 REQUEST}. OMISSIONS  ARE   {E8 DESIGNATED}  [***]. A COMPLETE VERSION OF THIS EXHIBIT  HAS   BEEN   {E9 FILED}  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Source: DOVA PHARMACEUTICALS INC., 10-Q,  11/8/2018

TABLE OF CONTENTS ( {E10 continued}  )

5.10 Manufacturing; Distribution; Marketing.  25

ARTICLE 6 FINANCIAL PROVISIONS 26

6.1 Promotion Fee.  26

6.2 Milestone Payment.  27

6.3 Reports; Payments.  27

6.4 Taxes.  28

6.5 Determination of Specialty.  29

ARTICLE 7 AUDIT RIGHTS 30

7.1 Recordkeeping.  30

7.2 Valeant Rights.  30

7.3 Dova Rights.  31

ARTICLE 8 INTELLECTUAL PROPERTY 32

8.1 Ownership of Intellectual Property.  32

8.2 Title to Trademarks and Copyrights.  32

8.3 Protection of Trademarks and Copyrights.  32

8.4 Disclosure of Know-How.  33

ARTICLE 9 CONFIDENTIALITY 33

9.1 Confidential Information.  33

9.2 Public Announcements.  34

ARTICLE 10 REPRESENTATIONS AND WARRANTIES; ADDITIONAL COVENANTS 35

10.1 Representations and Warranties of Dova.  35

10.2 Representations and Warranties of Valeant.  37

10.3 Disclaimer of Warranty.  38

10.4 Additional Covenants.  39

ARTICLE 11 INDEMNIFICATION; LIMITATIONS ON LIABILITY 39

11.1 Indemnification by Dova.  39

11.2 Indemnification by Valeant.  39

11.3 Indemnification Procedures.  40

11.4 Limitation of Liability.  40

11.5 Insurance.  40

ARTICLE 12 TERM AND TERMINATION 41

12.1  Term  .  41

12.2 Early Termination for Cause.  41

Source: DOVA PHARMACEUTICALS INC., 10-Q,  11/8/2018

12.3 Other Early Termination.  42

12.4 Effects of Termination.  42

12.5 Tail Period.  42

ii

CONFIDENTIAL {E148 TREATMENT}  HAS   BEEN   {E149 REQUESTED}  FOR PORTIONS OF THIS EXHIBIT. THE COPY  {E12 FILED}  HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY {E149 REQUEST}. OMISSIONS  ARE   {E13 DESIGNATED}  [***]. A COMPLETE VERSION OF THIS EXHIBIT  HAS   BEEN   {E14 FILED}  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Source: DOVA PHARMACEUTICALS INC., 10-Q,  11/8/2018

TABLE OF CONTENTS ( {E15 continued}  )

12.6 Survival.  43

ARTICLE 13 MISCELLANEOUS 43

13.1 Force Majeure.  43

13.2 Assignment.  43

13.3 Severability.  44

13.4 Notices.  44

13.5 Governing Law.  45

13.6 Dispute Resolution.  45

13.7 Waiver of Jury Trial.  45

13.8 Entire Agreement; Amendments.  46

13.9 Headings.  46

13.10 Independent Contractors.  46

13.11 Third Party Beneficiaries.  46

13.12 Waiver.  46

13.13 Cumulative Remedies.  46

13.14 Waiver of Rule of Construction.  46

13.15 Use of Names.  46

13.16 Further Actions and Documents.  47

13.17 Certain Conventions.  47

13.18 Counterparts.  47

iii

CONFIDENTIAL {E150 TREATMENT}  HAS   BEEN   {E151 REQUESTED}  FOR PORTIONS OF THIS EXHIBIT. THE COPY  {E17 FILED}  HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY {E151 REQUEST}. OMISSIONS  ARE   {E18 DESIGNATED}  [***]. A COMPLETE VERSION OF THIS EXHIBIT  HAS   BEEN   {E19 FILED}  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Source: DOVA PHARMACEUTICALS INC., 10-Q,  11/8/2018

CO-PROMOTION AGREEMENT

This Co-Promotion Agreement (this "Agreement") is  {E20 entered}  into and  {E21 dated}  as of  September 26, 2018  (the "Effective  Date  ") by and between Dova Pharmaceuticals, Inc., a Delaware corporation ("Dova"), and Valeant Pharmaceuticals North America LLC, a Delaware limited liability company ("Valeant"). Dova and Valeant are each  {E22 referred}  to individually as a "Party" and together as the "Parties". RECITALS

WHEREAS, Dova has  {E23 developed}  and has rights to market and  {E24 sell}  the Product (as  {E25 defined}  below) in the Territory;

WHEREAS, the Parties  {E26 believe}  that it would be mutually beneficial to  {E27 collaborate}  on promotional {E152 activities} for the Product and, accordingly, Dova desires that Valeant  {E29 conduct}  certain promotional {E154 activities}, and Valeant desires to  {E29 conduct}  such {E154 activities}, for the Product in the Territory;

NOW, THEREFORE, in consideration of the  {E30 following}  mutual promises and obligations, and for other good and valuable consideration the adequacy and sufficiency of which are hereby  {E31 acknowledged}  , the Parties  {E32 agree}  as  follows  :

CONFIDENTIAL {E155 TREATMENT}  HAS   BEEN   {E156 REQUESTED}  FOR PORTIONS OF THIS EXHIBIT. THE COPY  {E34 FILED}  HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY {E156 REQUEST}. OMISSIONS  ARE   {E35 DESIGNATED}  [***]. A COMPLETE VERSION OF THIS EXHIBIT  HAS   BEEN   {E36 FILED}  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Source: DOVA PHARMACEUTICALS INC., 10-Q,  11/8/2018

ARTICLE 1   DEFINITIONS

1.1 "Act" shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. Â§ 301 et seq., as it may be  {E37 amended}  from time to time, and the regulations  {E38 promulgated}  thereunder. 1.2 "Adverse {E158 Event}" shall mean any untoward medical {E158 occurrence} in a patient or clinical investigation subject who is  {E39 administered}  the Product, but which  does  not necessarily have a causal relationship with the {E159 treatment} for which the Product is  {E40 used}  . An "Adverse {E158 Event}" can  {E41 include}  any unfavorable and unintended sign ( {E42 including}  an abnormal laboratory finding), symptom or disease temporally  {E43 associated}  with the {E161 use} of the Product, whether or not  {E44 related}  to the Product. A pre-existing condition that  {E45 worsened}  in severity after administration of the Product would be  {E46 considered}  an "Adverse {E158 Event}". 1.3 "Affiliate" shall mean, with respect to any Person, any other Person that directly or indirectly  {E47 controls}  , is  {E48 controlled}  by or is under common control with such Person. A Person shall be  {E49 deemed}  to  {E50 control}  another Person if such Person  {E51 possesses}  the power to  {E52 direct}  or  {E53 cause}  the direction of the {E163 management}, business and policies of such Person, whether through the ownership of fifty percent (50%) or more (or such lesser percentage which is the maximum  {E54 allowed}  to be  {E55 owned}  by a foreign corporation in a particular jurisdiction) of the voting securities of such Person, by contract or otherwise. 1.4 "Agreement" shall have the meaning set forth in the preamble to this Agreement. 1.5 "Alliance Managers" shall have the meaning set forth in Section 4.1.4. 1.6 "Alternate Product" shall mean a pharmaceutical product that is  {E56 commercialized}  by Valeant or its Affiliates in the Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the event that such business segments are  {E57 restructured}  , that is part of the Salix business unit), and which product is complementary to the Product with regard to Target Professionals in the Specialty. 1.7 "Applicable Laws" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind whatsoever of any Governmental Authority in the Territory  {E58 pertaining}  to any of the {E164 activities} and obligations  {E59 contemplated}  by this Agreement,  {E60 including}  , as applicable, the Act, the Generic Drug Enforcement Act of  1992  (21 U.S.C. Â§ 335a et seq.), the Anti- Kickback Statute (42 U.S.C. Â§ 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of  1996 , the Federal False Claims Act (31 U.S.C. Â§Â§ 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers,  {E61 released}   April 2003 , the Antifraud and Abuse Amendment to the Social Security Act, the American Medical Association guidelines on gifts to physicians, generally  {E62 accepted}  standards of good clinical practices  {E63 adopted}  by  current  FDA regulations, as well as any state laws and regulations (i)  {E64 impacting}  the {E165 promotion} of pharmaceutical products, (ii)  {E65 governing}  the {E166 provision} of meals and other gifts to medical professionals,  {E66 including}  pharmacists, or (iii)  {E67 governing}  consumer

2

CONFIDENTIAL {E167 TREATMENT}  HAS   BEEN   {E168 REQUESTED}  FOR PORTIONS OF THIS EXHIBIT. THE COPY  {E69 FILED}  HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY {E168 REQUEST}. OMISSIONS  ARE   {E70 DESIGNATED}  [***]. A COMPLETE VERSION OF THIS EXHIBIT  HAS   BEEN   {E71 FILED}  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Source: DOVA PHARMACEUTICALS INC., 10-Q,  11/8/2018

protection and deceptive trade practices,  {E72 including}  any state anti-kickback/fraud and  {E73 abuse}  related laws, all as  {E74 amended}  from time to time. 1.8 "Business Day" means  each day  of the week,  {E75 excluding}   Saturday ,  Sunday  or  a day  on which banking institutions in New York, New York, USA are closed. 1.9 "Calendar Quarter" shall mean each successive period of three (3) calendar months  {E76 commencing}  on  January 1 ,  April 1 ,  July 1  and  October 1 , except that the first Calendar Quarter of the  Term  shall  {E77 commence}  on the Effective  Date  and  {E78 end}  on the  day  immediately prior to the first to  {E79 occur}  of  January 1 ,  April 1 ,  July 1  or  October 1  after the Effective  Date  , and the last Calendar Quarter shall  {E80 end}  on  the last day  of the  Term  . 1.10 "Calendar Year" shall mean each successive period of twelve (12) months  {E81 commencing}  on  January 1  and  {E82 ending}  on  December 31 , except that the first Calendar Year of the  Term  shall  {E83 commence}  on the Effective  Date  and  {E84 end}  on  December 31  of the  year  in which the Effective  Date   {E85 occurs}  , and the last Calendar Year of the  Term  shall  {E86 commence}  on  January 1  of the  year  in which the  Term   {E87 ends}  and  {E88 end}  on  the last day  of the  Term  . 1.11 "{E169 Claims}" shall mean all {E170 charges}, {E171 complaints}, {E172 actions}, {E173 suits}, {E174 proceedings}, {E175 hearings}, {E176 investigations}, {E177 claims}, {E178 demands}, {E179 judgments}, {E180 orders}, {E181 decrees}, {E182 stipulations} or {E183 injunctions}, in each case of a Third Party ( {E89 including}  any Governmental Authority). 1.12 "Code" shall mean the Code on {E184 Interactions} with Healthcare Professionals  {E90 promulgated}  by the Pharmaceutical Research and Manufacturers of America (PhRMA)/BIO, as it may be  {E91 amended}  . 1.13 "Compensation Report" shall have the meaning set forth in Section 4.2.2(b). 1.14 "Compliance Manager" shall have the meaning set forth in Section 4.3.9. 1.15 "Compliance Report" shall have the meaning set forth in Section 4.2.2(c). 1.16 "Confidential Information" shall mean all secret, confidential, non-public or proprietary Know-How, whether  {E94 provided}  in  {E93 written}  , oral, graphic, video, computer or other form,  {E94 provided}  by or on behalf of one Party to the other Party pursuant to this Agreement,  {E95 including}  information  {E96 relating}  to the  {E97 disclosing}  Party's  {E98 existing}  or  {E99 proposed}  {E185 research}, development {E186 efforts}, promotional {E187 efforts}, regulatory {E188 matters}, patent {E189 applications} or business and any other materials that have not been  {E100 made}  available by the  {E101 disclosing}  Party to the general public. All such information  {E102 related}  to this Agreement  {E103 disclosed}  by or on behalf of a Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be  {E104 deemed}  to be such Party's Confidential Information  {E105 disclosed}  hereunder. For purposes of clarity, (i) Dova's Confidential Information shall  {E106 include}  all Product Materials unless and until  {E107 made}  available by Dova to the general public ( {E108 including}  through Valeant) and (ii) the terms of this Agreement shall be  {E109 considered}  Confidential Information of both Parties. 1.17 "Confidentiality Agreement" shall have the meaning set forth in Section 9.1.1. 3

CONFIDENTIAL {E190 TREATMENT}  HAS   BEEN   {E191 REQUESTED}  FOR PORTIONS OF THIS EXHIBIT. THE COPY  {E111 FILED}  HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY {E191 REQUEST}. OMISSIONS  ARE   {E112 DESIGNATED}  [***]. A COMPLETE VERSION OF THIS EXHIBIT  HAS   BEEN   {E113 FILED}  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Source: DOVA PHARMACEUTICALS INC., 10-Q,  11/8/2018

1.18 " {E114 Designated}  Product" shall mean a specific pharmaceutical product  {E115 marketed}  by Valeant which is  {E116 agreed}  to in writing by the Parties on or prior to the Effective  Date  . 1.19 "{E194 Detail(s})" shall mean a Product {E194 presentation} during a face-to-face sales call between a Target Professional and a Sales Representative, during which a {E194 presentation} of the Product's attributes, benefits,  {E117 prescribing}  information and safety information are orally  {E118 presented}  , for {E196 use} in the Field in the Territory. Neither e-details, nor {E197 presentations}  {E119 made}  at {E198 conventions}, {E199 exhibit booths}, a {E200 sample drop}, educational {E201 programs} or {E202 speaker meetings}, or similar {E203 gatherings}, shall  {E120 constitute}  a {E194 Detail}. 1.20 "Detail Report" shall have the meaning set forth in Section 4.2.2. 1.21 "{E206 Dispute}" shall have the meaning set forth in Section 13.6.1. 1.22 "Dollar" or "$" shall mean United States dollar. 1.23 "Dova Trademarks and Copyrights" shall mean the logos, trade dress, slogans, domain names and housemarks of Dova or any of its Affiliates as may  {E121 appear}  on any Product Materials or Product Labeling, in each case, as may be  {E122 updated}  from time to time by Dova. 1.24 "Dova's Third Party Data Source" shall mean [***] or such other data source as  {E123 selected}  by Dova and with which Dova  {E124 enters}  into an agreement, at its cost. 1.25 "Effective  Date  " shall have the meaning set forth in the preamble to this Agreement. 1.26 "FDA" shall mean the United States Food and Drug Administration or any successor agency  {E125 performing}  comparable functions. 1.27 "Field" shall mean the {E207 treatment} of thrombocytopenia in adult patients with chronic liver disease who are  {E126 scheduled}  to  {E127 undergo}  a procedure and any and all additional indications for which the Product is  {E128 approved}  in the Territory. 1.28 "Field Force Personnel" shall mean collectively, the Sales Representatives, the members of the institutional account management team  {E129 described}  in Section 4.1.5, if any, that are  {E130 engaged}  in  {E194 Detailing}  the Product and any other employees of Valeant  {E132 engaged}  in the Valeant {E154 Activities}. 1.29 "GAAP" shall mean United States generally  {E133 accepted}  accounting principles. 1.30 "Governmental Authority" shall mean any court, agency, authority, department, regulatory body or other instrumentality of any government or country or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government or any supranational organization of which any such country is a member, which has competent and  {E134 binding}  authority to  {E135 decide}  ,  {E136 mandate}  ,  {E137 regulate}  , enforce, or otherwise  {E138 control}  the {E209 activities} of the Parties  {E139 contemplated}  by this Agreement. 4

CONFIDENTIAL {E192 TREATMENT}  HAS   BEEN   {E193 REQUESTED}  FOR PORTIONS OF THIS EXHIBIT. THE COPY  {E141 FILED}  HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY {E193 REQUEST}. OMISSIONS  ARE   {E142 DESIGNATED}  [***]. A COMPLETE VERSION OF THIS EXHIBIT  HAS   BEEN   {E143 FILED}  SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.



#COLOR:E145=hsl(0, 100%, 80%)
#COLOR:E147=hsl(25, 100%, 80%)
#COLOR:E149=hsl(50, 100%, 80%)
#COLOR:E151=hsl(75, 100%, 80%)
#COLOR:E29=hsl(100, 100%, 80%)
#COLOR:E154=hsl(125, 100%, 80%)
#COLOR:E156=hsl(150, 100%, 80%)
#COLOR:E158=hsl(175, 100%, 80%)
#COLOR:E168=hsl(200, 100%, 80%)
#COLOR:E94=hsl(225, 100%, 80%)
#COLOR:E191=hsl(250, 100%, 80%)
#COLOR:E194=hsl(275, 100%, 80%)
#COLOR:E193=hsl(300, 100%, 80%)

#TOKENIZATION-TYPE:1

